South Africa Approves Generic Version of Popular Weight-Loss Drug
South Africa’s health regulator has officially granted approval to the Indian company Sun Pharmaceutical Industries to manufacture and sell a generic version of the popular drug Ozempic. This decision marks a significant development for the local pharmaceutical market, as the drug is widely used for the treatment of type 2 diabetes and weight management.
Ozempic, which contains the active ingredient semaglutide, has seen a massive surge in global demand over the past few years. Because of this high demand, many countries, including South Africa, have faced supply shortages. The introduction of a generic alternative is expected to help address these availability issues for patients who rely on the medication.
Generic medicines are produced to be the same as brand-name drugs in terms of quality, strength, and safety. By allowing a generic version into the market, the South African Health Products Regulatory Authority (SAHPRA) aims to provide patients with more affordable and accessible treatment options.
While the approval has been granted, the company must still navigate the logistics of distribution across the country. Health experts suggest that this move could eventually lower costs for consumers and reduce the pressure on pharmacies that have struggled to keep up with the high number of prescriptions for semaglutide products.